Elotuzumab is named as an intervention in 7 current clinical trials in our USA, UK, China and India registers. 4 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Regeneron Pharmaceuticals (1). The most-studied condition is Multiple Myeloma. The EU clinical trials register (CTIS) separately lists 2 authorised or ongoing trials.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Elotuzumab. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination with Pomalidomide and Dexamethasone Versus Standard of Care in Patients with Multiple Myeloma who Have Received One to Three Prior Lines of Therapy
2025-524028-23-00 · CTIS ↗ · Neoplasms
|
Phase 3 | Ongoing | F. Hoffmann-La Roche AG | France, Germany, Italy + 5 more |
|
HO183 CAR T: A phase III randomized trial comparing academically produced BCMA-directed CAR T-cells (ARI0002h) with standard of care regimen in patients with relapsed/refractory multiple myeloma
2025-524876-43-00 · CTIS ↗ · Neoplasms
|
Phase 3 | Authorised | Universitair Medisch Centrum Groningen | Netherlands |
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
2 single-substance products containing Elotuzumab on the HPRA medicines list.
No entry for Elotuzumab in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Regeneron Pharmaceuticals | 1 |
| Janssen Research & Development, LLC | 1 |
| AbbVie | 1 |
| Pfizer | 1 |
| Celgene | 1 |
| Hoffmann-La Roche | 1 |
| Karyopharm Therapeutics Inc | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 7 | 4 |
| Clinical trials in UK | 4 | 2 |
| Clinical trials in China | 4 | 2 |
| Clinical trials in India | 1 | 0 |
| EU register (CTIS) | 2 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
7 current trials in our USA, UK, China and India registers name Elotuzumab as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of the 7 trials are recruiting: 4 with sites in USA, 2 with sites in UK and 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Regeneron Pharmaceuticals (1), Janssen Research & Development, LLC (1), AbbVie (1) and Pfizer (1), among 7 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 2 single-substance products containing Elotuzumab, for example Empliciti 300 mg powder for concentrate for solution for infusion. (Bristol-Myers Squibb Pharma EEIG). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Elotuzumab has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Elotuzumab works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Elotuzumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Elotuzumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.